EP2197885A1 - Augmentation de l'activité biologique in vivo de composés biologiquement actifs - Google Patents
Augmentation de l'activité biologique in vivo de composés biologiquement actifsInfo
- Publication number
- EP2197885A1 EP2197885A1 EP08802109A EP08802109A EP2197885A1 EP 2197885 A1 EP2197885 A1 EP 2197885A1 EP 08802109 A EP08802109 A EP 08802109A EP 08802109 A EP08802109 A EP 08802109A EP 2197885 A1 EP2197885 A1 EP 2197885A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- compound according
- biological activity
- formula
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 133
- 230000004071 biological effect Effects 0.000 title claims abstract description 41
- 238000001727 in vivo Methods 0.000 title abstract description 4
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical class C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 claims abstract description 44
- 230000000694 effects Effects 0.000 claims abstract description 21
- 230000001506 immunosuppresive effect Effects 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims description 51
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 19
- 229960002521 artenimol Drugs 0.000 claims description 19
- BJDCWCLMFKKGEE-ISOSDAIHSA-N artenimol Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-ISOSDAIHSA-N 0.000 claims description 19
- 229930016266 dihydroartemisinin Natural products 0.000 claims description 19
- 241000124008 Mammalia Species 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 17
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical group FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- UKXCIQFCSITOCY-VLDCTWHGSA-N anhydrodihydroartemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC=C4C UKXCIQFCSITOCY-VLDCTWHGSA-N 0.000 claims description 9
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical group CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 6
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 6
- 206010062016 Immunosuppression Diseases 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical group CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 5
- ROJKPKOYARNFNB-UHFFFAOYSA-N Propyl pentanoate Chemical group CCCCC(=O)OCCC ROJKPKOYARNFNB-UHFFFAOYSA-N 0.000 claims description 5
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims description 5
- JXTHNDFMNIQAHM-UHFFFAOYSA-M dichloroacetate Chemical group [O-]C(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-M 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 208000016097 disease of metabolism Diseases 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 3
- 230000001773 anti-convulsant effect Effects 0.000 claims description 3
- 239000001961 anticonvulsive agent Substances 0.000 claims description 2
- 229960003965 antiepileptics Drugs 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000007794 irritation Effects 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 abstract description 3
- 230000001679 anti-nematodal effect Effects 0.000 abstract description 3
- 230000000843 anti-fungal effect Effects 0.000 abstract description 2
- 230000004060 metabolic process Effects 0.000 abstract description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 60
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 54
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 43
- 229940079593 drug Drugs 0.000 description 32
- 230000015572 biosynthetic process Effects 0.000 description 17
- 230000008878 coupling Effects 0.000 description 17
- 238000010168 coupling process Methods 0.000 description 17
- 238000005859 coupling reaction Methods 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 16
- 239000007787 solid Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 239000002904 solvent Substances 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 7
- 230000002503 metabolic effect Effects 0.000 description 6
- 230000003285 pharmacodynamic effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- TWFZGCMQGLPBSX-UHFFFAOYSA-N carbendazim Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- -1 i.e. Chemical compound 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- PIYNUZCGMLCXKJ-UHFFFAOYSA-N 1,4-dioxane-2,6-dione Chemical compound O=C1COCC(=O)O1 PIYNUZCGMLCXKJ-UHFFFAOYSA-N 0.000 description 2
- LSEFXLGTUCVBPE-UHFFFAOYSA-N 1h-imidazol-2-ylcarbamic acid Chemical compound OC(=O)NC1=NC=CN1 LSEFXLGTUCVBPE-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- BJDCWCLMFKKGEE-KDTBHNEXSA-N Dihydroartemisinin (DHA) Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](O)[C@@H]4C BJDCWCLMFKKGEE-KDTBHNEXSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic acid anhydride Natural products CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000006013 carbendazim Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- BOQMASYCUFVXCR-LHJKONGQSA-N deoxoartemisinin Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC[C@@H]4C BOQMASYCUFVXCR-LHJKONGQSA-N 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000000855 fungicidal effect Effects 0.000 description 2
- 239000000417 fungicide Substances 0.000 description 2
- LSACYLWPPQLVSM-UHFFFAOYSA-N isobutyric acid anhydride Chemical compound CC(C)C(=O)OC(=O)C(C)C LSACYLWPPQLVSM-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- KSAPYRIVHFAQGR-UHFFFAOYSA-N 1-sulfanylbenzimidazole Chemical class C1=CC=C2N(S)C=NC2=C1 KSAPYRIVHFAQGR-UHFFFAOYSA-N 0.000 description 1
- PGZVFRAEAAXREB-UHFFFAOYSA-N 2,2-dimethylpropanoyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OC(=O)C(C)(C)C PGZVFRAEAAXREB-UHFFFAOYSA-N 0.000 description 1
- ZUSLEOOZAITYGH-UHFFFAOYSA-N 2-(aminomethyl)-3,5-ditert-butylphenol Chemical compound CC(C)(C)C1=CC(O)=C(CN)C(C(C)(C)C)=C1 ZUSLEOOZAITYGH-UHFFFAOYSA-N 0.000 description 1
- LDZYRENCLPUXAX-UHFFFAOYSA-N 2-methyl-1h-benzimidazole Chemical class C1=CC=C2NC(C)=NC2=C1 LDZYRENCLPUXAX-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000005497 Thymidylate Synthase Human genes 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940064305 adrucil Drugs 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940033488 antinematodal agent Drugs 0.000 description 1
- 239000002814 antineoplastic antimetabolite Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 229960004191 artemisinin Drugs 0.000 description 1
- 229930101531 artemisinin Natural products 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 229940099500 cystamine Drugs 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- JSRLJPSBLDHEIO-SHYZEUOFSA-N dUMP Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 JSRLJPSBLDHEIO-SHYZEUOFSA-N 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 229940099302 efudex Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229940064300 fluoroplex Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- RMIODHQZRUFFFF-UHFFFAOYSA-N methoxyacetic acid Chemical compound COCC(O)=O RMIODHQZRUFFFF-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 239000005645 nematicide Substances 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
Definitions
- the present invention relates to compounds with an increased in vivo biological activity, and especially an increased pharmaceutical activity, such as an anti-nematodal or antifungal activity, an immunosuppresive activity, a metabolism influencing activity and/or an anti-cancer activity.
- the present invention further relates to a method for preparing said compounds and the use of said compounds for the treatment of mammals, preferably humans, in need of treatment .
- the in vivo biological activity of a compound, and especially the pharmaceutical activity of a compound or a drug is determined, amongst others, by its pharmacokinetic parameters .
- pharmacokinetic parameters are used to describe the response of the human or animal body to a drug. Examples of such parameters are absorption of the drug by, distribution of the drug through, and metabolic conversion or degradation of the drug in the human or animal body.
- pharmacodynamic parameters are used to describe the response of the human or animal body to a drug.
- pharmacodynamic parameters relate to the mechanism of activity of a compound or drug such as a receptor agonistic or antagonistic activity, membrane disruption, suppression or activation of an immune response, DNA-binding, influencing chemical reactions, influencing signaling cascades, etc.
- Coupling such as covalently coupling or linking, other compounds to a known drug can greatly influence its pharmacokinetic parameters such as its absorption by, its distribution through and/or its metabolic conversion or degradation by the human or animal body.
- lowering the concentration of the drug to be administered or chancing the treatment regime could be provided in case the (covalently) coupled compounds decrease or increase the metabolic conversion of the drug depending on the pharmaceutically active form of the drug.
- the (covalently) coupled compound influences one or more pharmacodynamic parameters of a drug.
- the effect could be additional, i.e., the sum of the pharmaceutical activity of the (covalently) coupled compound and the drug, or synergistic.
- the (covalently) coupled compound in combination with the drug provides a not previous recognized or known beneficial pharmaceutical activity.
- an improved and beneficial therapeutic effect can be obtained through, for example, a reduction of the amount the drug to be administered.
- an improved beneficial therapeutic effect can be obtained because of the possibility to increase the concentration of the drug due to a decreased toxicity provided by, for example, an improved (local) distribution or an increased or decreased metabolic conversion.
- this object is met by a compound comprising an artemisinin derivative according to the general formula (I) :
- a compound with a biological activity preferably a pharmaceutical activity
- covalently coupling an artemisinin derivative according to the general formula (I) to a compound with biological activity, preferably a drug beneficially influences the biological activity, preferably the pharmaceutical activity, of said compound.
- the beneficial biological activity, preferably the pharmaceutical activity is provided by advantageously influencing one or more pharmacokinetic parameters of a biologically active compound, preferably a drug, such as its absorption by, its distribution through and/or its metabolic conversion by the human or animal body.
- covalently coupled artemisinin derivative according to the present invention possibly additionally, influences the biological activity, preferably the pharmaceutical activity, of said biologically active compound by providing one or more improved, or even novel, pharmacodynamic properties.
- the artemisinin derivative according to the general formula (I) comprises as starting compound at the 1 and/or 2 position at least one coupling group for reacting with the biologically active compound such as an -OH group.
- the artemisinin derivative starting compound according to the present invention can be further substituted at the 1 and/or 2 position with a C 1 to C 6 alkyl or aryl group, branched or unbranched, such as a methyl, ethyl or propyl group, preferably a methyl group.
- a C 1 to C 6 alkyl or aryl group branched or unbranched, such as a methyl, ethyl or propyl group, preferably a methyl group.
- One of the artemisinin derivatives according the general formula (I) of the present invention can be derived from a known intermediate of the biosynthesis of the antimalarial drug artemisinin, i.e., dihydroartemisinin (DHA) .
- DHA dihydroartemisin
- the 1 position of the initial artemisinin derivative comprises an -OH group allowing covalently coupling of a biologically active compound to the 1 position, for example, by an estrification reaction or an etherification reaction.
- AHA anhydrodihydroartemisinin
- This compound comprises a double bond between the 1 and 2 position allowing, through an intermediate reaction, covalently coupling of a biologically active compound to the 1 position or the 2 position, for example, by a nucleophile reaction of 0, N or S to provide the corresponding derivatives at the 1 position, or a hydroxylation reaction by an anti-markofnikoff addition at position 2.
- the artemisinin derivative according to the present invention is derived from a compound chosen from the group consisting of dihydroartemisinin, anhydrodihydroartemisinin and deoxartemisinin
- the biologically, preferably pharmaceutically, active compound is coupled to the artemisinin derivative according to the present invention, such as anhydrodihydroartemisinin, through a sulfide (-S-), ether (-0-) , ester (-OCO-)or amine (-N-) linkage.
- a sulfide (-S-) ether (-0-) , ester (-OCO-)or amine (-N-) linkage.
- Particularly preferred in this embodiment of the present invention are sulfide (-S-) and ether (-O-) linkages.
- the compound with a biological activity of the present invention is covalently linked to the artemisinin derivative of the present invention at the 1 position of a compound according to the general formula (I) .
- the compound with a biological activity of the present invention is covalently linked to the artemisinin derivative of the present invention at the 2 position of a compound according to the general formula (I) .
- the biologically active compound covalently coupled to the artemisinin derivative is methyl N-(IH- benzimidazol-2-yl) carbamate .
- Methyl N- (lH-benzimidazol-2-yl) carbamate is an anti- nematodal agent, and particularly a fungicide, also known under a number of synonyms such as carbendazim, carbendazole, mecarzole, funaben, etc.
- Covalently coupling methyl N- (lH-benzimidazol-2- yl) carbamate with an artemisinin derivative according to the present invention beneficially improves the anti-nematodal, and particularly, the fungicide activity of this drug.
- the present invention provides a compound according to formula (II) :
- the biologically active compound covalently coupled to an artemisinin derivative according to the present invention is methoxyacetetic acid.
- Methoxyacetetic acid is an immunosuppresive agent also known as methoxyethanoic acid or 2-methoxyacetetic acid. Covalently coupling methoxyacetetic acid with an artemisinin derivative according to the present invention beneficially improves the immunosuppresive activity of this drug.
- the present invention provides a compound according to formula (IV) :
- the biologically active compound covalently coupled to an artemisinin derivative according to the present invention is 2, 2-dichloroacetate .
- 2, 2-dichloroacetate influences glucose metabolism, lowers lactate and activates the dehydrogenase complex.
- Covalently coupling 2, 2-dichloroacetate with a artemisinin derivative according to the present invention beneficially improves, amongst others, the metabolic influencing activity of this drug.
- the present invention provides a compound according to formula (V) :
- the biologically active compound covalently coupled to the artemisinin derivative according to the present invention is 5-fluoro-lH-pyrimidine-2, 4-dione .
- 5-fluoro-lH-pyrimidine-2, 4-dione is an antineoplastic anti-metabolite. It interferes with DNA synthesis by blocking thymidylate synthase conversion of deoxyuridylic acid to thymidylic acid.
- 5-fluoro-lH-pyrimidine-2, 4-dione is also known under the synonyms fluorouracil, fluoroplex, adrucil, efudex, timazin, etc.
- Covalently coupling 5-fluoro-lH-pyrimidine-2, 4-dione with an artemisinin derivative according to the present invention beneficially improves especially the anti-cancer activity of this drug.
- the present invention provides a compound according to formula (VI) :
- the biologically active compound covalently coupled to the artemisinin derivative according to the present invention is acetate.
- Acetate is used, amongst others, internally as a counterirritant and also as a reagent.
- Covalently coupling acetate with an artemisinin derivative according to the present invention beneficially improves especially the counterirritant activity of this drug.
- the present invention provides a compound according to formula (VII) :
- the biologically active compound covalently coupled to the artemisinin derivative according to the present invention is iso-butyrate .
- Iso-butyrate has, amongst others, an antiproliferative effect. It is has an effect on acetylation and deacetylation of histones, thereby having an effect on cell growth control, differentiation and apoptosis.
- Covalently coupling iso-butyrate with an artemisinin derivative according to the present invention beneficially improves especially the anti-proliferative activity of this drug.
- the present invention provides a compound according to formula (VIII) :
- the biologically active compound covalently coupled to an artemisinin derivative according to the present invention is butyrate.
- Butyrate is, amongst others, a histamine antagonist
- Covalently coupling butyrate with an artemisinin derivative according to the present invention beneficially improves especially the histamine antagonistic activity of this drug.
- the present invention provides a compound according to formula (IX) :
- the biologically active compound covalently coupled to the artemisinin derivative according to the present invention is propylpentanoate .
- Propylpentanoate is a fatty acid with anticonvulsant properties used in the treatment of epilepsy.
- Propylpentanoate is also known under the synonyms valproic acid, epilim, convulex, eurekene, labazene, selenica, orfiril, valerin, etc. Covalently coupling propylpentanoate with an artemisinin derivative according to the present invention beneficially improves especially the anticonvulsant activity of this drug.
- the present invention provides a compound according to formula (X) :
- the present invention also relates to intermediate products of the compounds according to the present invention according to formula (XI) :
- the present invention relates to a method for obtaining a compound according to the present invention, wherein the method comprises covalently linking an artemisinin derivative as defined above with a compound with a biological activity as defined above through sulfide (-S-), ether (-O-) , ester (-OCO-) or amine (-N-) linkage at the 1 or 2 position thereby increasing the biological activity of said biologically active compound.
- the invention also relates to the use of an artemisinin derivative as defined above for increasing the biological activity of a compound as defined above.
- the present invention relates to a compound as defined above for use as a medicament.
- the present invention relates to the use of a compound as defined above for the preparation of a medicament for treating a mammal, preferably a human, in need of such treatment.
- the present invention relates to the use of a compound as defined above for the preparation of a medicament for treating a mammal, preferably a human, suffering from a nematodal infection, wherein the compound having a biological activity is me'thyl N- (lH-benzimidazol-2-yl) carbamate .
- the present invention relates to the use of a compound as defined above for the preparation of a medicament for treating a mammal, preferably a human, in need of immunosuppression wherein the compound having a biological activity is methoxyacetetic acid.
- the present invention relates to the use of a compound as defined above for the preparation of a medicament for treating a mammal, preferably a human, suffering from a metabolic disease, wherein the compound having a biological activity is 2, 2-dichloroacetate .
- the present invention relates to the use of a compound as defined above for the preparation of a medicament for treating a mammal, preferably a human, suffering from a metabolic disease, in need of immunosuppression or especially from cancer, wherein the compound having a biological activity is 5-fluoro-lH-pyrimidine-2, 4-dione .
- the present invention relates to the use of a compound as defined above for the preparation of a medicament for treating a mammal suffering from irritation, wherein the compound having a biological activity is acetate.
- the present invention relates to the use of a compound as defined above for the preparation of a medicament for treating a mammal suffering from cancer, wherein the compound having a biological activity is iso-butyrate .
- the present invention relates to the use of a compound as defined above for the preparation of a medicament for treating a mammal in need of immunosuppression, wherein the compound having a biological activity is butyrate.
- Example 1 General synthesis of the artemisinin derivatives according to the present invention
- R 1 and R 2 are H or a biologically active molecule according to the present invention under the provision that at least R 1 or R 2 is a biologically active molecule according to the present invention.
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des composés qui présentent une activité in vivo accrue et notamment une activité pharmaceutique accrue, par exemple une activité anti-nématode ou antifongique, une activité immunosuppressive, une activité influençant le métabolisme et/ou une activité anti-cancéreuse. La présente invention concerne notamment un composé qui comprend un dérivé d'artémisinine selon la formule générale (I) relié par une liaison covalente à la position 1 ou 2 à un composé qui présente une activité biologique, augmentant ainsi l'activité biologique dudit composé, ou un de ses sels pharmaceutiquement acceptables.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08802109A EP2197885A1 (fr) | 2007-09-10 | 2008-09-10 | Augmentation de l'activité biologique in vivo de composés biologiquement actifs |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2007/007868 WO2009033494A1 (fr) | 2007-09-10 | 2007-09-10 | Augmentation de l'action biologique in vivo de composés biologiquement actifs |
| EP08802109A EP2197885A1 (fr) | 2007-09-10 | 2008-09-10 | Augmentation de l'activité biologique in vivo de composés biologiquement actifs |
| PCT/EP2008/007556 WO2009033706A1 (fr) | 2007-09-10 | 2008-09-10 | Augmentation de l'activité biologique in vivo de composés biologiquement actifs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP2197885A1 true EP2197885A1 (fr) | 2010-06-23 |
Family
ID=42174213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP08802109A Withdrawn EP2197885A1 (fr) | 2007-09-10 | 2008-09-10 | Augmentation de l'activité biologique in vivo de composés biologiquement actifs |
Country Status (1)
| Country | Link |
|---|---|
| EP (1) | EP2197885A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012017004A1 (fr) * | 2010-08-03 | 2012-02-09 | Dafra Pharma N.V. | Nouveaux dérivés de type artémisinine possédant des propriétés cytotoxiques et antiangiogènes |
-
2008
- 2008-09-10 EP EP08802109A patent/EP2197885A1/fr not_active Withdrawn
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2009033706A1 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012017004A1 (fr) * | 2010-08-03 | 2012-02-09 | Dafra Pharma N.V. | Nouveaux dérivés de type artémisinine possédant des propriétés cytotoxiques et antiangiogènes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8692003B2 (en) | Increasing the in vivo biological activity of biologically active compounds | |
| FI113173B (fi) | Menetelmä uusien terapeuttisesti käyttökelpoisten taksaanijohdannaisten valmistamiseksi | |
| CA2496477C (fr) | Synthese d'epothilones, leurs intermediaires, leurs analogues et leurs utilisations | |
| EP1064285B1 (fr) | Nouveaux derives de cephalotaxane et leur procede de fabrication | |
| RS57157B1 (sr) | Acc inhibitori i njihove primene | |
| M Heravi et al. | Applications of Barton-McCombie reaction in total syntheses | |
| HUT73418A (en) | Process for preparing rapamycin carbonate esters and pharmaceutical compositions of immunosuppressive activity containing said compounds | |
| SK133096A3 (en) | Rapamycin hydroxyesters, process for their preparation and pharmaceutical compositions containing them | |
| CN106866419A (zh) | 一类萜酯化合物及其制备方法和用途 | |
| EP2786982A1 (fr) | Dérivés amino-propylène-glycol, procédé de préparation, composition pharmaceutique et utilisation correspondante | |
| AU2017339786B2 (en) | Bryostatin compounds and methods of preparing the same | |
| Morita et al. | Synthesis and structure–activity relationships of cassiarin A as potential antimalarials with vasorelaxant activity | |
| CN103974965B (zh) | 唾液酸类似物 | |
| CA3122066A1 (fr) | Conjugues de monomethyl fumarate et d'un porteur et leurs methodes d'utilisation | |
| EP2197885A1 (fr) | Augmentation de l'activité biologique in vivo de composés biologiquement actifs | |
| Zhang et al. | Efficient synthesis of jusbetonin, an indolo [3, 2-b] quinoline glycoside, and its derivatives | |
| DE2402804A1 (de) | Adenosinderivate | |
| EP1753419B1 (fr) | Dimeres dihydroartemisinin et dihydroartemisitene anticancereux et antiprotozoaires à fonctionnalités chimiques désirées | |
| WO2014068506A2 (fr) | Compositions et procédés pour le traitement de maladies autoimmunes | |
| CN107043373B (zh) | 一种噁三唑类no供体型他汀衍生物及其制备方法和应用 | |
| US10155777B2 (en) | Trans-cycloheptenes and hetero-trans-cycloheptenes for bioorthogonal coupling | |
| AU2023216716A1 (en) | Inducers of klf2 and methods of use thereof | |
| WO2005049619A1 (fr) | Molecules duales contenant un derive peroxydique, leur synthese et leurs applications therapeutiques | |
| WO2014068459A2 (fr) | Compositions et méthodes de traitement de la douleur et de maladies neurologiques | |
| US11964956B2 (en) | Cannabinergic compounds and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20100330 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
| 17Q | First examination report despatched |
Effective date: 20100827 |
|
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20160330 |